Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]

The following table sets forth the common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:

	For the Three Months Ended
	March 31,		March 31,
	2019		2018
Restricted stock units/awards		1,065,317		714,999
Preferred shares		250,000		250,000
Options		-		20,000
Total potential dilutive effect		1,315,317		984,999